web analytics

Lithium-Driven Neural Inhibition Devices For Chronic Pain And Local Anesthesia

Published:
Lead Inventor: Bozhi Tian
Print or Save to PDF

SUMMARY

An implantable bioelectronic device platform enabling targeted, programmable inhibition of neural activity through lithium ion delivery, offering durable local anesthesia and pain relief without systemic toxicity

The Unmet Need: Programmable pain management and local anesthesia solutions featuring targeted delivery and durable inhibition with minimal invasiveness

  • Chronic pain affects over 50 million Americans and millions more globally, creating a substantial healthcare and economic burden. Current methods of local pain relief and anesthesia rely on repeated drug injections or bulky, externally driven devices, leading to inefficiencies, patient discomfort, and elevated risk profiles. Conventional electrical or physical approaches require harsh operating conditions, high voltages, or suffer from limited duration of effect.

  • Lithium, while known for its neural inhibition properties, is typically administered systemically, causing side effects. The need for compact, implantable, and energy-efficient devices with precise, localized control has been rising in parallel with the demand for non-opioid, programmable pain solutions. Adoption of solid-state, mineral-based electrodes in biomedical applications is accelerating, but most lack molecular specificity or stability necessary for longer-term implants. The healthcare industry is shifting toward innovations that reduce procedural frequency, lower lifetime costs, and deliver sustained neural modulation.

The Proposed Solution: A platform leveraging mineral-electrode lithium chemistry in a programmable, thin-film implant to deliver precise, sustained neural inhibition and local anesthesia

  • The faculty inventor developed a novel implantable bioelectronic device for local anesthesia and pain relief enables on-demand, programmable neural inhibition using lithium electrochemistry. Constructed from a stable, biocompatible mineral (LiFePO4), the device delivers localized lithium ions to target neural tissues, effectively blocking pain signal conduction for hours following operation. Unlike current drug-based or electrical approaches, this technology offers sustained effects, high storage capacity, and minimal invasiveness, without requiring external reservoirs or complex architectures. The platform is adaptable for both peripheral and central nervous system targets, with demonstrated in vivo biocompatibility. Its simple, scalable fabrication process supports integration into surgical and pain management workflows.

ADVANTAGES

ADVANTAGES

  • Precise, on-demand neural inhibition

  • Implantable for chronic or repeat use

  • Reduced risk of systemic side effects

  • High storage capacity and stability in-vivo

  • Low-voltage, energy-efficient operation

  • Simple fabrication and miniaturization for surgical integration

APPLICATIONS

  • Chronic pain management (neuropathy, sciatica, post-operative pain)

  • Neuromodulation for movement disorders or targeted neural inhibition

  • Local anesthesia for surgical and dental procedures

PUBLICATIONS

  • Demonstrated in preclinical models; in vivo biocompatibility and efficacy validated